Arthur Kirsch Sells 10,000 Shares of Liquidia (NASDAQ:LQDA) Stock

Liquidia Corporation (NASDAQ:LQDA) Director Arthur Kirsch sold 10,000 shares of the business’s stock in a transaction dated Wednesday, June 3rd. The shares were sold at an average price of $54.80, for a total value of $548,000.00. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Liquidia Trading Up 11.9%

LQDA opened at $62.32 on Friday. Liquidia Corporation has a one year low of $11.85 and a one year high of $66.24. The company has a debt-to-equity ratio of 1.18, a current ratio of 2.22 and a quick ratio of 2.03. The business has a 50 day simple moving average of $46.27 and a two-hundred day simple moving average of $39.40. The firm has a market capitalization of $5.54 billion, a price-to-earnings ratio of 445.20 and a beta of 0.58.

Liquidia (NASDAQ:LQDA) last posted its earnings results on Monday, May 11th. The company reported $0.52 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.41 by $0.11. The firm had revenue of $132.87 million for the quarter, compared to analysts’ expectations of $119.44 million. Liquidia had a return on equity of 46.82% and a net margin of 7.74%.Liquidia’s revenue for the quarter was up 4187.1% compared to the same quarter last year. Analysts predict that Liquidia Corporation will post 2.97 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the business. Caprock Group LLC bought a new position in shares of Liquidia during the 3rd quarter valued at $37,114,000. Apis Capital Advisors LLC purchased a new position in shares of Liquidia in the 3rd quarter worth $9,569,000. Farallon Capital Management LLC increased its position in Liquidia by 102.1% during the third quarter. Farallon Capital Management LLC now owns 8,565,638 shares of the company’s stock valued at $194,783,000 after acquiring an additional 4,326,876 shares during the last quarter. GSA Capital Partners LLP increased its position in Liquidia by 63.6% during the fourth quarter. GSA Capital Partners LLP now owns 63,176 shares of the company’s stock valued at $2,179,000 after acquiring an additional 24,555 shares during the last quarter. Finally, Tudor Investment Corp ET AL purchased a new stake in Liquidia during the third quarter valued at $1,536,000. Hedge funds and other institutional investors own 64.54% of the company’s stock.

Analyst Ratings Changes

Several research analysts have commented on the stock. Jefferies Financial Group restated a “buy” rating and issued a $60.00 price objective on shares of Liquidia in a report on Monday, May 11th. Needham & Company LLC lifted their target price on shares of Liquidia from $54.00 to $70.00 and gave the company a “buy” rating in a research note on Monday, May 11th. HC Wainwright boosted their price target on shares of Liquidia from $55.00 to $67.00 and gave the company a “buy” rating in a research report on Tuesday, May 12th. Weiss Ratings restated a “sell (d-)” rating on shares of Liquidia in a report on Tuesday, April 21st. Finally, Wall Street Zen raised Liquidia from a “buy” rating to a “strong-buy” rating in a research report on Saturday, May 16th. Three investment analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and two have given a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $53.50.

Liquidia Company Profile

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).